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ABSTRACT
Adipose tissue secretes a plethora of adipokines as evidenced by characterization 
of subcutaneous and visceral adipose tissue secretomes. However, adipose tissue 
composition and secretion pattern is depot and disease dependent, influencing the 
adipose tissue secretome. We investigated the secretome of cancer-associated adipose 
tissue (CAAT) explants from breast cancer patients and explored its role in breast cancer 
proliferation. CAAT proteins were identified by LC-MS/MS and human protein antibody 
arrays and stimulated proliferation of three breast cancer cell lines. Kinomics and 
transcriptomics of MCF-7 breast cancer cells treated with the secretome of CAAT revealed 
activation of Akt-, ERK- and JNK-pathways and differential expression of activator protein 
1 (AP-1) and cAMP responsive element-binding protein (CREB) target genes. The cyclin-
dependent kinase (CDK)4/6-inhibitor palbociclib significantly abrogated CAAT-enhanced 
breast cancer cell proliferation. Our work characterizes the specific breast CAAT protein 
secretome and reveals its pro-proliferative potency in breast cancer. 
INTRODUCTION
In breast cancer, adipose tissue is the main 
component of the tumor environment and the 
heterogeneous cell types of the adipose tissue stimulate 
breast cancer cells towards further progression. Adipocytes 
can drive breast cancer progression by lipid transfer, 
androgen-to-estrogen production and secretion of several 
adipokines [1–3]. Human adipose tissue-derived stem 
cells isolated from breast tumors promote breast cancer 
growth through secretion of several growth factors and 
interleukin(IL)-8 [4]. Endothelial progenitor cells derived 
from human adipose tissue enhance tumor growth and 
metastasis through increased tumor vasculature when 
co-injected with human breast cancer cells in orthotopic 
mouse models [5]. Adipose tissue macrophages linked with 
obesity and chronic inflammation are described as tumor 
growth promoters [6]. Secretome analysis of separate 
adipose tissue-derived cell types has been performed and 
can be useful for designing potential therapeutic strategies 
[7, 8]. However, they do not reflect the secretome of 
adipose tissue as a whole and neglect important bilateral 
communication between different adipose tissue cell types 
influencing the adipose tissue secretome. 
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Adipose tissue can be found throughout the body 
but its composition and secretion pattern differs and is 
influenced by its localisation in the body and disease states 
such as obesity and cancer [9–11]. This implicates that 
available adipose tissue secretome data cannot be simply 
extrapolated when studying the paracrine effects of breast 
CAAT. 
We performed the first proteomic analysis of the 
human breast CAAT secretome and explored its influence 
on biological processes, pathways and transcription factors 
involved in breast cancer growth. 
RESULTS
Secretome analysis of CAAT secreted soluble 
factors
To identify adipose tissue secreted proteins, we 
analysed a discovery set of CMCAAT from 6 patients from 
which 2 CMCAAT were used for LC-MS/MS analysis 
and 4 CMCAAT for antibody array as low levels of 
highly bioactive proteins are often not detected by gel-
electrophoresis-based techniques [12]. A total of 668 
proteins were identified (Supplementary Table 1) and 
proteins were assigned to several biological processes 
like signal transduction (18,1%), metabolism (14,5%), 
energy pathways (14%), protein metabolism (11, 6%), cell 
growth and/or maintenance (10%) and immune response 
(6,2%) (Figure 1A). CAAT proteins activate transcription 
factors like Krüppel-like factor 7 (KLF7) (36, 9%), JUN 
(20, 2%), FOS (20, 2%) and NFE2 (7, 5%) (Figure 1B). 
A detailed overview of the biological pathways and 
functions each of the 668 proteins belong to can be found 
in Supplementary Table 2. To validate these finding we 
made use of CMCAAT from an additional 18 patients. In 
16 patients, the concentration of 5 identified proteins 
was measured by ELISA, i.e. leptin (9.1 ± 5.1 ng/ml), 
adiponectin (267.2 ± 101.5 ng/ml), IL-6 (25.1 ± 7.5 ng/ml), 
CSF-1 (2.8 ± 1.0 ng/ml) and CCL22 (0.1 ± 0.1 ng/ml) 
(Figure 1C). Western blot identified leptin, adiponectin 
and fatty acid binding protein 4 (FABP4) in CMCAAT of 
the two remaining patients (Figure 1E). As adipose tissue 
is composed of several cell types, we separated breast 
cancer-associated adipose tissue from 10 breast cancer 
patients into TAA and SVF. RT-qPCR revealed expression 
of adiponectin in TAA (35-fold higher expression in 
TAA vs SVF, p = 0.005). In contrast, a 5-fold higher 
IL-6 (p = 0.005) and a 4-fold higher CCL22 expression 
(p = 0.005) in SVF compared to TAA were observed. 
CSF-1 did not significantly differ in both fractions 
(p = 0.959) (Figure 1D). Comparison of our detected 
proteins in CAAT with the visceral adipose tissue 
secretome from Alvarez-Llamas et al. [13] containing 
259 proteins revealed 153 common proteins (24,6%). 
CAAT proteins were also compared with the secretome of 
isolated human adipocytes from non-obese subcutaneous 
adipose tissue from Lehr et al. [14] and Xie et al. [15], and 
showed a 32,3% (199 proteins) and 15,8% (295 proteins) 
overlap respectively (Figure 1F). A detailed description 
of the common proteins between the different data sets is 
provided in Supplementary Table 3.
CAAT stimulates proliferation of breast cancer 
cells
As JUN and FOS are both proto-oncogenes involved 
in cell proliferation, we investigated the effect of CAAT 
on breast cancer cell proliferation. MCF-7 aggregates 
were confronted with CAAT in native type I collagen, the 
main structural component of the mammary gland. Next 
to clear reorganisation of the aggregate, CAAT induces 
a strong proliferation rate of MCF-7 breast cancer cells 
as evidenced by Ki67-staining, with 88,1% of MCF-
7 cells showing a positive nuclear signal. In contrast, 
MCF-7 aggregates not confronted with CAAT lost their 
proliferative ability after a few days of culture (difference 
CAAT to no CAAT = 86,9%, 95% CI = 83,1% to 90,7%, 
p < 0,0001) (Figure 2A). We next questioned if soluble 
factors secreted by CAAT could be responsible for the 
effects on proliferation as seen by direct co-culture. 
Treatment of three breast cancer cell lines with CMCAAT 
led to a significant higher number of cells in time (Con vs 
CMCAAT; MCF-7 at day 9: 26 × 103 ± 5 × 103 vs 83 × 103 
± 7 × 103, p = 0.0003; T47D at day 9: 135 × 103 ± 13 × 103 
vs 783 × 103 ± 91 × 103, p = 0.0003; MDA MB 231 at 
day 9: 580x103 ± 60 × 103 vs 4133 × 103 ± 301 × 103, 
p = 0.0001) (Figure 2B). Positive cell cycle regulators 
Cyclin A and Cyclin E were increased in CMCAAT treated 
breast cancer cells compared to control, while negative 
cell cycle regulators p27 and p21 remained unchanged 
(Figure 2C). A phospho kinase array revealed less 
activation of p27 in MCF-7 breast cancer cells upon 
CMCAAT treatment (Figure 2D). 
Regulation of AP-1 and CREB transcription 
factors in CAAT mediated breast cancer growth
As CAAT soluble factors were able to stimulate 
breast cancer cell proliferation, we further explored the 
influence of CAAT on pro-proliferative pathways in 
breast cancer cells. As shown in our previous publication, 
phospho kinase screening revealed a clear activation of 
ERK1/2- (1.75-fold), Akt- (1.75-fold), JNK- (1.94-fold) 
and CREB- (2.02-fold) pathways in CMCAAT treated MCF-7 
cells when compared to control [16]. Western blot 
analysis confirmed these results in three breast cancer 
cell lines except for CREB activation in MDA MB 231 
cells (Figure 3A). CAAT secretome analysis identified 113 
proteins (20,2%) playing a role in JUN/FOS expression. 
Activation of c-JUN and c-FOS was confirmed by Western 
blot in both MCF-7 and T47D cells but not in MDA MB 
231 cells. Activated c-Jun and c-Fos proteins form homo- 
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or heterodimers binding the activator protein 1 (AP-1) 
binding site in DNA followed by transcriptional activation 
[17]. Micro-array analysis of MCF-7 cells treated with 
CMCAAT revealed several AP-1 transcriptional targets of 
which the upregulated gene ETS2 (ETS proto-oncogene 
2; 2.5-fold) and the downregulated genes RGS2 (regulator 
of G-protein signaling 2; 14.8-fold), EMP1 (epithelial 
membrane protein 1; 6.5-fold), DUSP2 (dual specificity 
phosphatase 2; 3.4-fold) and GADD45B (growth arrest 
and DNA damage inducible beta; 2.8-fold) are linked 
with a pro-proliferative signature in breast cancer [18–22] 
(Figure 3B). As CREB was clearly activated on phospho 
kinase screening and Western blot analysis, we also 
looked at CREB transcriptional genes in CMCAAT treated 
MCF-7 cells and found an upregulation of LDHA 
(lactate dehydrogenase A; 2.1-fold) and downregulation 
of GEM (GTP binding protein overexpressed in skeletal 
muscle; 19.2-fold), ATF3 (activating transcription factor 
Figure 1: Secretome analysis of CAAT secreted soluble factors. (A) pie chart, biological processes annotated to CAAT secreted 
factors. (B) bar chart, transcription factors annotated to CAAT secreted factors. (C) scatter plots of leptin, adiponectin, IL-6, CCL22 
and CSF-1 concentrations in CMCAAT from 16 breast cancer patients measured by ELISA. (D) scatter plots of relative mRNA levels of 
adiponectin, IL-6, CCL22 and CSF-1 in TAA and SVF of CAAT from 10 breast cancer patients. (E) Western blot analysis identifies leptin, 
adiponectin and FABP4 in CMCAAT from 2 breast cancer patients. (F) Area-proportional Venn diagrams visualizing unique and common 
proteins between CAAT and three available data sets.
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3; 11.1-fold), DUSP1 (dual specificity phosphatase 1; 
5.4-fold) and PER1 (period circadian clock 1; 2.5-fold), 
known to affect breast cancer proliferation and growth 
[23–29] (Figure 3B). Interestingly, protein analysis of 
CMCAAT revealed 30 proteins (5,4%) involved in CREB-
mediated transcription. RT-qPCR validated the differential 
expression of 4 of the above mentioned AP-1 and CREB 
transcriptional targets (Con vs. CMCAAT, p = 0.004 for all 
genes except DUSP2 p = 0.197) (Figure 3C). 
Impact of palbociclib on CAAT enhanced breast 
cancer cell proliferation
Proliferation of cancer cells requires entry of the cell 
into the cell cycle comprising different sequential stages 
tightly controlled by cyclins and CDKs, amongst others. 
As CAAT proteins are able to significantly stimulate breast 
cancer cell proliferation (Figures 2A, 2B, 4A and 4B), we 
evaluated the effect of palbociclib, a selective CDK4/6-
inhibitor, on CMCAAT enhanced proliferation of MCF-7, 
T47D and MDA MB 231 breast cancer cells. Palbociclib 
significantly reduced the stimulatory effect of CAAT in 
all cell lines (MCF-7 and T47D: CM vs. CM + palbo, 
p = 0.001 for all palbociclib concentrations; MDA MB 
231: CM vs. CM + palbo, p = 0.035 at 50 nM, p = 0.009 
at 100 nM, p = 0.005 at 200 nM, p = 0.002 at 400 nM and 
p = 0.001 at 800 nM palbociclib) (Figure 4B). 
DISCUSSION
Several studies have described the secretome of 
isolated and in vitro cultured adipogenic differentiated 
mesenchymal stem cells, adipose tissue-derived adipocytes 
and stromal vascular fraction, and ex vivo cultured visceral 
adipose tissue [13, 14, 30, 31]. To our knowledge, we 
characterized for the first time the secretome of ex vivo 
cultured human breast cancer-associated adipose tissue 
and identified the capacity of the CAAT secretome to 
Figure 2: CAAT stimulates proliferation of breast cancer cells. (A) Ki67 staining of MCF-7 spheroids cultured in CAAT or 
collagen type I (SC is 100μm). (B) graphs representing proliferation tests of MCF-7, T47D or MDA MB 231 cells treated with control 
medium (Con) or CMCAAT; *p = 0.0989, **p = 0.0093, ***p = 0.0003, °p = 0.0187, °°p = 0.0007, °°°p = 0.0003, ^ p = 0.0327, ^ ^p = 0.0093, 
^^p = 0.0001. (C) Western blot analysis of cyclin A, cyclin E, p27 and P21 in MCF-7, T47D or MDA MB 231 cells treated for 48 h with 
Con or CMCAAT, tubulin serves as internal control. The image shows the results of 1 of 3 repeats (n = 3) with each time 3 biological repeats. 
(D) phospho kinase array (part B) indicating phosphorylation levels of p27 in MCF-7 cells treated for 48 h with Con or CMCAAT, 
NC = negative control (Of note, NC1, RS1 and RS2 are shown in part A of the phospho kinase array displayed in Figure 2A of our previous 
publication [12]).
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activate several pro-proliferative pathways in different 
breast cancer cell lines.
Our study has some limitations that need to be 
pointed out. First, we used CAAT from a limited number 
of breast cancer patients with diverse clinical and 
pathological characteristics (Supplementary Table 4). 
Second, we did not compare our results with normal breast 
adipose tissue. The main reason for this is that adipose 
tissue is a complicated and adaptive organ influenced by 
different factors form the environment making it difficult 
to determine ‘normal’ (breast) adipose tissue (see next 
paragraph). Third, our functional experiments are mainly 
performed with breast cancer cells cultured as adherent 
cells to plastic. We did not use 3D-tests with breast cancer 
cell organoids in matrigel or collagen, resembling more 
closely the in vivo situation. 
The secretome of adipose tissue is subject to many 
determinants. First, adipose tissue is dispersed all over the 
body but not all adipose tissue is equal [32]. For example, 
subcutaneous and visceral abdominal adipose tissue is 
biologically and genetically distinct [9, 11, 33]. Second, 
adipose tissue is composed of many different cell types like 
adipocytes, macrophages, endothelial cells, mesenchymal 
stem cells, etc. and each cell type contributes to the adipose 
tissue secretome [34, 35]. Third, certain disease states such 
as obesity and cancer alter the composition of adipose 
tissue and influence its secretion pattern [10, 11, 36]. In 
light of this, we used patient-derived explant culture of 
breast cancer-associated adipose tissue instead of plastic-
adherent adipocyte precursors stimulated to adipocyte 
differentiation. Of note, this also explains the variability 
in adipokine levels between different patients as seen in 
Figure 3: CAAT enhanced breast cancer proliferation correlates with differential activation of AP-1 and CREB 
dependent genes. (A) Western blot analysis of (p-)Erk, (p-)Akt, (p-)c-JUN, (p-)c-FOS and (p-)CREB in MCF-7, T47D and MDA MB 
231 cells treated for 48 h with Con or CMCAAT. (B) relative fold change of indicated AP-1 and CREB genes in MCF-7 cells treated for 
48 h with CMCAAT compared to control. (C) relative mRNA levels of indicated genes in MCF-7 cells treated for 48 h with Con or CMCAAT.
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Figure 1C. As we did not find a significant correlation 
between BMI and adipokine levels (results not shown), 
other micro or macro environmental factors must play a 
role in the adipose tissue secretion pattern.
Proteome analysis of CAAT-secreted factors 
revealed a large number of proteins involved in energy 
pathways and metabolism, which reflects the normal 
adipose tissue function and has been described by others 
[31, 37]. When investigating the affected biological 
pathways, more than 30% of adipose tissue proteins 
are linked with regulation of KLF7 transcription factor. 
Krüppel-like factors are drivers of cell proliferation and 
differentiation in different organ systems and many of 
them play a role in fat biology [38]. In human adipocytes, 
KLF7 expression is involved in adipogenesis, obesity and 
type 2 diabetes [39–41]. Both the biological process and 
transcription factor analysis confirmed the adipose nature 
of our CAAT proteome and this was further validated by 
ELISA (leptin and adiponectin), qPCR (adiponectin) and 
Western blot analysis (leptin, adiponectin and FABP4) on 
CMCAAT derived from multiple patients. Physical separation 
of adipocytes from SVF revealed unique expression 
patterns with leptin and adiponectin dominantly expressed 
in adipocytes, and IL-6 and CCL22 dominantly expressed 
in SVF. Ultimately, we compared our 668 CAAT proteins 
with available data sets from human visceral abdominal 
adipose tissue [13] and isolated adipocytes from human 
subcutaneous adipose tissue [14, 15]. A substantial 
proportion of proteins was retraced in the three data sets 
(Supplementary Table 3). However, as expected, CAAT 
secretome has a unique secretion profile with multiple 
proteins not previously identified. This indicates that at 
least a part of our proteome will represent breast CAAT 
specific proteins, useful when studying paracrine effects 
of adipose tissue in breast cancer. Whether the identified 
proteins are breast adipose tissue specific or cancer 
specific will need more research using comparison of 
adipose tissue from non-cancer patients or from other sites 
Figure 4: Palbociclib effectively inhibits CAAT enhanced breast cancer cell proliferation. (A) graph representing 
proliferation test of MCF-7 cells treated with Con, Con + 100 nM palbociclib, CMCAAT or CMCAAT + 100 nM palbociclib. The graph represents 
the results of 1 biologic experiment with 3 replicates. (B) graphs representing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT)-tests of MCF-7, T47D or MDA MB 231 cells treated with Con, CMCAAT and palbociclib at indicated concentrations; 
*p < 0.001, **p = 0.001, °p = 0.035, °°p = 0.009, °°°p = 0.005, °°°°p = 0.002. 
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in a breast cancer patient (e.g. breast adipose tissue versus 
visceral adipose tissue).
c-Jun and c-Fos are both proto-oncogenes and their 
homo- or heterodimers form the transcription factor AP-1, 
linked with cell proliferation, differentiation and survival 
[17, 42, 43]. A variety of growth factors, chemokines and 
cytokines stimulate the expression of c-Jun and c-Fos. 
Several of them like CCL22, four and a half LIM domains 
protein 1 (FHL1) and leukemia inhibiting factor (LIF) 
were detected in the breast CAAT proteome and have 
been linked with breast cancer proliferation and growth 
[44–47]. The transcriptional activity of c-Jun and c-Fos 
was stimulated by ERK, JNK and CREB signaling and 
their activation was detected by phospho kinase screening 
and Western blot in hormone-dependent MCF-7 and T47D 
breast cancer cells. However, we were not able to validate 
this pathway activation in hormone-independent MDA 
MB 231 cells where levels of p-ERK, p-c-Jun, p-c-Fos and 
p-CREB remained unchanged upon CMCAAT treatment. This 
indicates that CAAT proteins are able to enhance MDA 
MB 231 cell proliferation via other pathways than c-Jun 
and c-Fos. Moreover, Hardy et al. describes the influence 
of free fatty acids (FFAs) like oleate and palmitate on 
Akt-activation and subsequent cell proliferation in MDA 
MB 231 cells demonstrating that not only proteins but 
also FFAs can exert a pro-proliferative effect [48]. This 
correlates with Western blot analysis showing activation 
of the Akt-pathway in CMCAAT treated MDA MB 231 
cells. As our research focused on breast cancer-associated 
adipose tissue proteins, further research will be necessary 
to elucidate the role of FFAs in breast cancer.
Palbociclib has recently been FDA approved for 
use in combination with letrozole for the treatment of 
postmenopausal women with estrogen receptor-positive, 
human epidermal growth factor (HER)2-negative 
advanced breast cancer as initial endocrine-based therapy 
for their metastatic disease. Palbociclib inhibits CDK4 
and 6 to bind cyclin D1, keeping the tumor suppressor 
retinoblastoma protein (pRb) in its activated form 
and halting cell cycle progression [49, 50]. In vitro 
experimentation showed that palbociclib is most effective 
in estrogen receptor positive breast cancer cell lines [51]. 
This correlates with our observation that proliferation 
of hormone-dependent MCF-7 and T47D breast cancer 
cells was significantly inhibited upon palbociclib 
treatment, while this effect was not observed in hormone-
independent MDA MB 231 breast cancer cells. On the 
contrary, we see a significant, dose dependent increase in 
palbociclib treated MDA MB 231 cells  (non treated with 
CMCAAT). A possible explanation of these findings may be 
that CDK4/6 inhibition induces a compensatory mitogenic 
response as has been described in ER+/HER2- models 
[52]. In these models, the increased mitogenic signals due 
to palbociclib treatment were completely suppressed when 
the ER signaling pathway was simultaneously blocked by 
administration of an ER antagonist. This explains why the 
most positive clinical results are seen when palbociclib is 
combined with an endocrine therapy like the aromatase 
inhibitor letrozole in ER+/HER2- breast cancer patients. 
It is possible that in MDA MB 231 cells, which lack 
concurrent ER signaling, there is no mechanism present 
that could overrule the compensatory mitogenic signaling 
elicited by CDK4/6 inhibition. Further research will be 
necessary to test this hypothesis. 
In contrast with the results in MDA MB 231 cells 
in control conditions, palbociclib was able to significantly 
inhibit CAAT-enhanced proliferation of all three breast 
cancer cell lines.  This might signify that CAAT shifts the 
cell cycle control in MDA MB 231 cells from a non-pRb-
regulated to a pRb-regulated way, sensitizing the breast 
cancer cells to CDK4/6 inhibitory treatment. This is 
supported by the fact that MDA MB 231 is a pRb-positive 
cell line, which is an absolute necessity for sensitivity to 
palbociclib treatment [53, 54]. Moreover, a MDA MB 
231 orthotopic xenograft model showed a significant 
inhibition of the proliferation marker Ki67 by treatment 
with palbociclib [52]. These in vivo results correlate with 
our results of palbociclib-induced inhibition of CMCAAT-
stimulated proliferation of MDA MB 231 cells given the 
fact that CMCAAT-treated MDA MB 231 cells resemble 
more closely the in vivo situation (MDA MB 231 cells 
injected into the mammary fat pad) than MDA MB 231 
cells grown in absence of adipose tissue-derived factors 
(in vitro situation with control medium). 
This the first report identifying patient-derived 
breast cancer-associated adipose tissue proteins 
representing potential therapeutic targets of paracrine 
signalling implicated in breast cancer growth. 
MATERIALS AND METHODS
Cell lines
MCF-7, T47D and MDA MB 231 cell lines were 
obtained from American Type Culture Collection (ATCC, 
Manassas, VA). Cells were maintained in Dulbecco’s 
minimal essential medium (DMEM) supplemented with 
10% fetal calf serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin (Invitrogen, Carlsbad, CA) and 2.5 μg/mL 
fungizone (Bristol-Meyers Squibb, Brussels, Belgium). 
Every month cell cultures were tested for Mycoplasma 
contamination using MycoAlert Plus kit (Lonza, Verviers, 
Belgium).
Antibodies and reagents
Primary antibodies used for Western blot analysis 
and immunohistochemistry: mouse monoclonal anti-
Ki67 (clone MIB-1) (Dako, Glostrup, Denmark), mouse 
monoclonal anti-cyclin A and anti-cyclin E (Invitrogen, 
Carlsbad, CA), mouse monoclonal anti-p27 and anti-p21 
(Santa Cruz Biotechnology, Heidelberg, Germany), mouse 
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monoclonal anti-tubulin (Sigma-Aldrich, St Louis, MO), 
rabbit monoclonal anti-phospho-p44/42 MAPK (Erk1/2), 
anti-p44/42 MAPK (Erk1/2), anti-phospho-Akt, anti-Akt, 
anti-phospho-c-Jun, anti-c-Jun, anti-phospho-c-Fos, anti-
c-Fos, anti-phospho-CREB, anti-CREB (Cell Signaling 
Technology, Danvers, MA). Secondary antibodies coupled 
to horseradish peroxidase were obtained from Amersham 
Pharmacia Biotech (Diegem, Belgium). Palbociclib (PD-
0332991) was purchased at Selleck Chemicals (Munich, 
Germany). 
Conditioned medium of CAAT (CMCAAT), 
isolation of tumor-associated adipocytes (TAA) 
and stromal vascular fraction (SVF)
CAAT was obtained from breast cancer patients 
undergoing mastectomy at Ghent University Hospital 
in accordance with local ethics committee and written 
informed consent was obtained from all subjects 
(Supplementary Table 4). CMCAAT preparation and 
separation of adipose tissue in TAA and SVF were 
previously described [16]. In short, CAAT was washed, 
cut into pieces and placed in 6-well plates with DMEM/
F12 + 0.5% BSA (= control medium) on a nutating mixer 
at 37°C and 5% CO2. After 24 h, CM
CAAT is harvested, 
centrifuged, filtered, aliquoted and stored at –80°C until 
experimentation. For separation of CAAT into TAA and 
SVF, CAAT is washed, thoroughly minced and digested 
with collagenase. After centrifugation, the upper layer 
containing TAA is separated from SVF and RNA of both 
fractions was extracted using RNeasy Plus Universal Kit 
(Qiagen, Venlo, The Netherlands). Supplementary Table 5 
demonstrates the use of CMCAAT throughout the article.
Mass spectrometry
CMCAAT samples were run on NuPAGE 4%-20% 
Bis-Tris gradient gels (Invitrogen) in SDS-containing 
denaturation buffer, stained with 0.5% Coomassie Brilliant 
Blue (Bio-Rad) in 40% methanol and 10% acetic acid for 
20 minutes, and destained. Gel bands were processed and 
analyzed by LC-MS/MS as previously described [16, 55]. 
Protein analysis
Samples for western blot were prepared, runned and 
immunostained as described in [55].  Human L507 array 
(Raybiotech, Norcross, GA) was used to detect relative 
levels of 507 proteins in CMCAAT. Human phospho-kinase 
antibody array (R&D systems) was used to detect relative 
phosphorylation levels of 44 kinases. Concentrations of 
human leptin, adiponectin, IL-6, C-C motif chemokine 
22 (CCL22) and colony stimulating factor 1 (CSF-1) 
in CMCAAT were measured with a Duoset or Quantikine 
ELISA Kit (R&D systems). Scanning densitometry was 
carried out with the Quantity One Program (Bio-Rad, 
Hercules, CA). Functional analysis of detected proteins 
was performed using FunRich version 2.1 [56]. Venn 
diagrams were created with BioVenn software (www.cmbi.
ru.nl/cdd/biovenn/).
Microarray analysis
Total RNA was isolated using the Nucleospin RNA 
II kit (Macherey-Nagel, Düren, Germany) including 
DNAse I treatment. Quality control was performed using 
Agilent 2100 Bioanalyser (Agilent Technologies). Total 
RNA (0.5 μg) was processed and analysed on Human GE 
Agilent 4 × 44K microarrays. Four biological samples 
were studied. Data can be found on GEO (GEO accession 
number GSE58574).
Quantitative real-time PCR (RT-qPCR)
RNA was isolated using RNeasy Plus Universal Kit 
(Qiagen) including DNAse I treatment. cDNA synthesis and 
SYBR Green I RT-qPCR were carried out as described in 
[57]. Prime PCR assays for ADIPOQ (Adiponectin), IL-6, 
CCL22, CSF-1, ETS2, DUSP2, EMP1 and GEM were 
purchased at Bio-Rad. RNA quality index (RQI > 8) was 
assessed using Experion software (version 3.2, Bio-Rad).
Proliferation test and MTT-assay
For proliferation tests, 20.000 cells were seeded in 
culture flasks with normal growth medium for 24 h. Every 
three days, cells were washed with serum-free medium 
and control medium or CMCAAT with control medium (ratio 
1:1) was added.  On day 3, 6 and 9, cells were trypsinized 
and counted with Countess Automated Cell Counter (Life 
Technologies-Invitrogen, Gent, Belgium).
For MTT-assays, 2000 cells were seeded in a 96-
well plate with normal growth medium for 24 h. Cells were 
washed with serum-free medium and control medium, 
CMCAAT with control medium (ratio 1:1) and/or palbociclib 
were added and refreshed after 2 days. On day 5, 40 μl/well 
of 1 mg/ml MTT-solution was added and incubated 
for 2 h protected from light.  Supernatant was removed 
and the formazan crystals were dissolved in 100 μl/well 
DMSO. Optical density was measured with a Spectramax 
Paradigm Multi-Mode Microplate Reader (Molecular 
Devices, Sunnyvale, CA).
Statistics
Statistical analyses were performed using IBM 
SPSS Statistics 21.0 software (Chicago, IL). Continuous 
data were analysed with Mann-Whitney U test (mean 
± standard deviation) or Student’s t-test (difference of 
means and 95% confidence interval) where appropriate. 
Statistical tests were two-sided, p-values less than 0.05 
were considered statistically significant.
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